Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ambiante Health & Wellness vs Medro

Ambiante Health & Wellness
Graded #448

Lower grade

vs+8.600000000000001
Medro
Graded #252

Higher grade

The verdict

Medro takes it — 63.6/100 to 55/100.

Medro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, via a partner medical group and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMedro +5
45
50
Dose & formulationMedro +37
40
77
Clinical oversightAmbiante Health & Wellness +7
78
71
Labs & monitoringAmbiante Health & Wellness +1
53
52
FulfillmentMedro +27
65
92
Contract termsAmbiante Health & Wellness +22
55
33
Ambiante Health & Wellness · left barMedro · right bar

The numbers

MetricAmbiante Health & WellnessMedro
WeighScore55/10063.6/100
GradeCC
Scorecard rank#448#252
SemaglutideNot disclosed$199/mo (compounded)
TirzepatideNot disclosed$299/mo (compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only

Strengths

  • Compounded semaglutide and tirzepatide plus a low-dose GLP-1 "Longevity Microdose" option, all provider-guided
  • Concierge model: dedicated provider, direct secure messaging, provider-directed dosing, and structured check-ins
  • Every plan bundles compounded medication, provider care, and discreet direct delivery with no hidden fees
  • No charge if you are not approved; published support hours (Mon-Fri, 9am-5pm ET) by phone and email

Where it loses points

  • GLP-1 program pricing is not published on the site — quoted only after provider review, so cost is not comparable up front
  • Compounding pharmacy partners are not publicly named (a transparency gap for medication sourcing)
  • No brand-name Wegovy, Zepbound, Mounjaro, or Ozempic — compounded formulations only
  • State availability is not published; private-pay only, and the practice serves women, so it is not a fit for everyone
  • No LegitScript or PCAB accreditation displayed on the marketing site
Medro

Graded #252 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard